Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 3:1-20.
doi: 10.1007/s12281-023-00464-2. Online ahead of print.

Epidemiology of COVID-19-Associated Mucormycosis

Khadija Tayabali  1 , Hussein Pothiwalla  2 , Shivakumar Narayanan  1
Affiliations
Review

Epidemiology of COVID-19-Associated Mucormycosis

Khadija Tayabali et al. Curr Fungal Infect Rep. .

Abstract

Purpose of the review: To describe the epidemiology and risk factors for Coronavirus disease-19 (COVID-19)-associated mucormycosis (CAM) based on current published literature.

Recent findings: COVID-19 is associated with an increased risk of secondary infections. Mucormycosis is an uncommon invasive fungal infection that typically affects people with immunocompromising conditions and uncontrolled diabetes. Treatment of mucormycosis is challenging and is associated with high mortality even with standard care. During the second wave of the COVID 19 pandemic, an abnormally high number of CAM cases were seen particularly in India. Several case series have attempted to describe the risk factors for CAM.

Summary: A common risk profile identified for CAM includes uncontrolled diabetes and treatment with steroids. COVID-19-induced immune dysregulation as well as some unique pandemic specific risk factors may have played a role.

Keywords: COVID-19; Mucormycosis; Rhino-orbito-cerebral; Steroid therapy; Zygomycosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestDr. Narayanan reports grants from Regeneron Pharmaceuticals, outside the submitted work. Dr Tayabali and Pothiwalla declare that they have no conflicts of interest.

References

    1. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021;16(5):e0251170. doi: 10.1371/journal.pone.0251170. - DOI - PMC - PubMed
    1. Manna S, Baindara P, Mandal SM. Molecular pathogenesis of secondary bacterial infection associated to viral infections including SARS-CoV-2. J Infect Public Health. 2020;13(10):1397–1404. doi: 10.1016/j.jiph.2020.07.003. - DOI - PMC - PubMed
    1. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol. 2021;27(1):83–88. doi: 10.1016/j.cmi.2020.07.041. - DOI - PMC - PubMed
    1. Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7:1127–40. - PMC - PubMed
    1. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944–9e9. doi: 10.1016/j.cmi.2019.11.021. - DOI - PubMed

LinkOut - more resources